Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145540 | 0.88 | ABCB11 (0.61) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3145527 | 0.88 | ABCB11 (0.61) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3048648 | 0.87 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3048642 | 0.87 | ABCB11 (0.62) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3048644 | 0.87 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950634 | 0.85 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950631 | 0.85 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL3150378 | 0.85 | ABCB11 (0.57) | ABCB11LMNAMEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL3144395 | 0.84 | ABCB11 (0.57) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950574 | 0.84 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | claimed |
| EP-2364704-A1 | Combination of beta-adrenoceptor agonist and corticosteroid | AstraZeneca AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | CCR1, CCR5, CCR3 | ABCB11 1009/4885LMNA 3862/4885MEN1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.